The therapeutic potential of chemokine-toxin fusion proteins

IDrugs

Volumn 4, Issue 4, 2001, Pages 427-442

  McDonald, John R ^a   McManaman, James L ^a   Yong, Voon Wee ^a  

^a Osprey Pharmaceutical Limited   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747014754     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (236)

1. All H, Haribabu B, Richardson RM, Snyderman R: Mechanisms of inflammation and leukocyte activation. Med Clin North Am (1997) 81:1-28.
2. Zhang P, Summer WR, Bagby GJ, Nelson S: Innate immunity and pulmonary host defense. Immunol Rev (2000) 173:39-51.
3. Hesselgesser J, Horuk R: Chemokine and chemokine receptor expression in the central nervous system. J Neurovirol ( 1999) 5:13-26.
4. Mahida YR: The key role of macrophages in the Irnmunopathogenesls of inflammatory bowel disease. Inf/amm Bowel Dis (2000) 6:21-33.
5. Engelhard! E, Toksoy A, Goebeler M, Debus S, Brocker EB, Gilltaer R: Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol(W98) 153:1849-60.
6. Wang JM, Deng X, Gong W, Su S: Chemokines and their role In tumor growth and metastasis. J Immunol Methods (1998) 220:1-17.
7. Reischmann RM: Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: focus on etanercept, a new biologic response modifier. Clin Ther(\999] 21:1427-42.
8. Carteron ML Cytokines in rheumatoid arthritis: trials and tribulations. Mol Med Today (2000) 6:315-323.
9. Gasparini G: The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs (1999) 58:17-38.
10. Griffioen AW, Motema G: Angiogenesis: potentials for pharmacologie intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev(2000) 52:237-68. This review discusses the limitations of anti-angiogenic BRMs as the sole treatment of cancer.
11. Faden AI, Salzman S: Pharmacological strategies in CNS trauma. Trends Pharmacol Sei(1992) 13:29-35.
12. Gagliardi RJ: Neuroprotection, excitotoxicicity and NMDA antagonists. Arq Neuro Psiquiatr (2000) 58:583-588.
13. Trist DG: Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications. Pharm Acta Hetv (2000) 74:221-9.
14. Pin D, Werner P, Raine CS: Glutamate excitotoxicity In a model of multiple sclerosis. War/Wed (2000) 6:67-70.
15. Smith T, Groom A, Zhu B, Turski L: Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Wal Med (2000) 6:62-6.
16. Wiseman LR, Faulds D: Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. [published erratum appears in Drugs (2000) 59:476] Drugs (1999) 58:1029-42.
17. Opal SM, Rsher Jr CJ, Dhainaut JF, Vincent JL, Erase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crif Care Med(1997) 25:1115-24.
18. Vincent JL, Slotman G, Van Leeuwen PA, Shelly M, Nasraway S, Tenaillon A, Bander J, Friedman G: IL-1ra administration does not Improve cardiac function in patients with severe sepsis. J Crif Care (1999) 14:69-72.
19. Ghirnikar RS, Lee YL, Eng LF: Chemokine antagonist Infusion attenuates cellular infiltration following spinal cord contusion injury in rat. J Neurose! Res (2000) 59:63-73. In a rat model of spinal cord contusion injury, infusion of the broad-spectrum viral chemokine vMIPII attenuates leukocyte Infiltration. Reduced neuronal loss and gliosis is correlated with fewer activated macrophages at the site of injury.
20. Plater-Zyberk C, Hoogewerf AJ, Proudfoot AE, Power CA, Wells TN: Effect of a CC chemokine receptor antagonist on collagen Induced arthritis in DBA/1 mice. Immunol Lett ( 1997) 57:117-20.
21. Trapp BD, Bo L, Mork S, Chang A: Pathogenesis of tissue injury in MS lesions. J Neuroimmunol (1999) 98:49-56.
22. Ransohotf RM: Mechanisms of inflammation in MS tissue: adhesion molecules and Chemokines. J Neuroimmunol (\999) 98:57-68.
23. Ostergaard C, Yieng-Kow RV, Benfield T, Frimodt-Moller N, Espersen F, Lundgren JD: Inhibition of leukocyte entry into the brain by the selectin blocker fucoldin decreases interleukin-1 (IL-1) levels but increases IL-8 levels in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. Infect Immun (2000) 68:3153-7.
24. Loetscher P, Moser B, Daggiolini M: Chemokines and their receptors In lymphocyte traffic and HIV infection. Adv Immunol (2000) 74:127-80.
25. Mennfcken F, MaW R, de Souza EB, Quirion R: Chemokines and chemokine receptors in the CMS: a possible role in neuroinflammation and patterning. Trends Pharmacol Sd (1999) 20:73-8.
26. Bacon KB, Harrison JK: Chemokines and their receptors in neurobiology: perspectives in physiology and homeostasls. J Neuroimmunol(2000) 104:92-7.
27. McDonald JR, Ong M, Shen C, Parandoosh Z, Sosnowski B, Bussen S, Houston LL: Large-scale purification and characterization of recombinant fibroblast growth factor-saporin mitotoxin. Protein ExprPunï(1996) 8:97-108.
28. Chandler LA, Sosnowski BA, McDonald JR, Price JE, Aukerman SL, Baird A, Pierce GF, Houston LL: Targeting tumor cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein. IntJ Cancer(1998) 78:106-11.
29. Beers R, Chowdhury P, Bigner D, Pastan I: Immunotoxins with increased activity against epidermal growth factor receptor vlllexpressing cells produced by antibody phage display. Clin Cancer Res (2000) 6:2835-43.
30. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res (2000) 6:2157-65.
31. Glennie MJ, Johnson PW: Clinical trials of antibody therapy. Immunol Today (2000) 21:403-10.
32. Kreitman RJ: Immunotoxins in cancer therapy. Curr Opin Immunol (1999)11:570-8. See reference 34.
33. Brinkmann U: Recombinant antibody fragments and immunotoxin fusions for cancer therapy. In Vivo (2000) 14:21-7. See reference 34.
34. Frankel AE, Kreitman RJ, Sausville EA: Targeted toxins. Clin Cancer fles (2000) 6:326-34. Along with reference 32 and 33, this review updates the progress of ligandtoxin fusion protein technology over the years, and discusses the limitations and steps taken to improve this technology. With two fusions (Ontak from Seragen and Mylotarg from Celltech GroupWyerth-Ayerst Research) approved by the PDA, others awaiting PDA approval (eg, Bexxar from Corixa/GlaxoSmithKline and Zevalin from IDEC) and numerous immunotoxins in clinical trials, cell-targeting therapeutics (at least for cancer) appear to be the new wave of biotechnology drugs. The exploitation of new ligand-receptor systems should broaden the scope for therapeutic intervention to a wide range of diseases in addition to cancers.
35. Clark M: Antibody humanization: a case of the 'Emperor's new clothes'? Immunol Today (2000) 21:397-402.
36. Hudson PJ: Recombinant antibody constructs in cancer therapy. CurrOpin Immunol (1999) 11:548-57.
37. van Spriel AB, van Ojik HH, van De Winkel JG: Immunotherapeutic perspective for bispecific antibodies. Immunol Today (2000) 21:391-7.
38. Gorier A, Men S: Immune evasion of tumor cells using membranebound complement regulatory proteins. Immunol Today (1999) 20:576-82.
39. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P. Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A, Lister TA: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Onco/(2000) 18:317-24.
40. Dyer MJ: The role of CAMPATH-1 antibodies in the treatment of lymphold malignancies. Semin Onco/(1999) 26:52-7.
41. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, Epenetos A, Gisselbrecht C, Huhn D, Jaeger U, Thomas J, Marcus R, Nissen N, Poynton C, Rankin E, Stahel R, Uppenkamp M, Willemze R, Mellstedt H: CAMPATH-1 H monoclonal antibody in therapy for previously treated low- grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1 H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol (1998)16:3257-63.
42. Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, Stumxk RD, Coblyn JS, Maier AL, Spreen WR, Manna VK et af. CAMPATH-1 H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum (1995) 38:1589-94.
43. Matteson EL, Yocum DE, St Clair EW, Achkar AA, Thakor MS, Jacobs MR, Hays AE, Heitman CK, Johnston JM: Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1 H administered by daily subcutaneous injection. Arthritis Rheum (1995) 38:1187-93.
44. Gottlieb A, Krueger JG, Bright R, Ling M, Lebwohl M, Kang S, Feldman S, Spellman M, Wittkowski K, Ochs HD, Jardieu P, Bauer R, White M, Dedrick R, Garovoy M: Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol (2000) 42:42835.
45. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, üghtfoot R, Calabrese L, Zelinger DJ, Woody JN et at. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, CM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum (1995) 38:1581-8.
46. Rep MH, van Dosten BW, Roos MT, Ader HJ, Polman CH, van Lier RA: Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFNgamma secreting TH1 cells in humans. J Clin Invest (1997) 99:222531.
47. van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Rudge P, McDougall A, McLeod JG, Ader HJ, Polman CH: Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-7412: results of a randomized, double-blind, placebo-controlled, MR- monitored phase II trial. Neurology (1997) 49:351-7.
48. Isaacs JD, Burrows N, Wing M, Keogan MT, Rebello PR, Watts RA, Pye RJ, Morris P, Hazelman BL, Hale G, Waldmann H: Humanized antiCD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin Exp Immunol (1997) 110:158-66.
49. Schulze-Koops H, Davis LS, Haverty TP, Wacholtz MC, üpsky PE: Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a nondepleting humanized monoclonal antibody to CD4. J Rheumatol (1998)25:2065-76.
50. Siegall CB: Targeted toxins as anticancer agents. Cancer (1994) 74:1006-12.
51. Coll-Fresno PM, Batoz M, Tarquin S, Birnbaum D, Coulier F: Cytotoxic activity of a diphtheria toxin/FGF6 mitotoxin on human tumour cell lines. Oncogene(1997) 14:243-7.
52. Pai LH, Pastan I: Clinical trials with Pseudomonas exotoxin immunotoxins. Curr Top Microbiol Immunol (1998) 234:83-96.
53. Stirpe F, Barbieri L, Battelli MG, Soria M, Lappi DA: Ribosomeinactivating proteins from plants: present status and future prospects. Biotechnology (1992) 10:405-12.
54. Suh JK, Hovde CJ, Robertas JD: Shiga toxin attacks bacterial ribosomes as effectively as eucaryotic ribosomes. Biochemistry (1998)37:9394-8.
55. Skinner LM, Jackson MP: Inhibition of prokaryotic translation by the Shiga toxin enzymatic subunit. Microb Pathog (1998) 24:117-22.
56. Barbieri L, Valbonesi P, Bonora E, Gorini P, Bolognesi A, Stirpe F: Polynucleotide:adenosine glycosidase activity of ribosomeinactivating proteins: effect on DNA, RNA and poly(A). Nucleic Acids Res (1997) 25:518-22.
57. Barbieri L, Valbonesi P, Brigotti M, Montanaro L, Stirpe F, Sperti S: Shiga-like toxin I is a po!ynucleotide:adenosine glycosidase. Mol Microbiol (1998) 29:661-2.
58. Bolognesi A, Tazzari PL, Olivieri F, Polito L, Falini B, Stirpe F: Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. IntJ Cancer (1996) 68:349-55.
59. Bolognesi A, Polito L, Olivieri F, Valbonesi P, Barbieri L, Battelli MG, Carusi MV, Benvenuto E, Del Vecchio Blanco F, Di Maro A, Parente A, Di Loreto M, Stirpe F: New ribosome-lnactivating proteins with polynucleotide:adenosine glycosidase and antiviral activities from Basella rubra L. and Bougainvillea spectabiiis Willd. Planta (1997) 203:422-9.
60. Keppler-Hafkemeyer A, Brinkmann U, Pastan I: Role of caspases In immunotoxin-induced apoptosls of cancer cells. Biochemistry (1998)37:16934-42.
61. Chen C, Mattar SG, Hughes JD, Pierce GF, Cook JE, Ku DN, Hanson SR, Lumsden AB: Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic Intimai hyperplasla in the arteriovenous graft. Circulation (1996) 94:1989-95.
62. Färb A, Lee SJ, Min DH, Parandoosh 2, Cook J, McDonald J, Pierce GF, Virmani R: Vascular smooth muscle cell cytotoxicity and sustained inhibition of neolntimal formation by fibroblast growth factor 2-saporin fusion protein. Circ Res (1997) 80:542-50.
63. Mattar SG, Hanson SR, Pierce GF, Chen C, Hughes JD, Cook JE, Shen C, Noe BA, Suwyn CR, Scott JR, Lumsden AB: Local infusion of FGFsaporin reduces Intimai hyperplasia. J Surg Res (1996) 60:339-44.
64. Behar-Cohen FF, David T, D'Hermies F, Pouliquen YM, Buechler Y, Nova MP, Houston LL, Courtois Y: In vivo inhibition of lens regrowth by fibroblast growth factor 2-saporin. Invest Ophthalmol Vis Sei (1995)36:2434-48.
65. Behar-Cohen FF, David T, Buechler Y, Nova MP, Houston LL, Pouliquen YM, Courtois Y: Cytotoxic effects of FGF2-saporin on bovine epithelial lens cells in vitro. Invest Ophthalmol Vis Sc/(1995) 36:2425-33.
66. Henslee-Downey PJ, Parrish RS, MacDonald JS, Romond EH, Marciniak E, Coffey C, Ciocci G, Thompson JS: Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant Transplantation (1996)61:738-45.
67. Martin PJ, Nelson BJ, Appelbaum FR, Anasetti C, Deeg HJ, Hansen JA, McDonald GB, Nash RA, Sullivan KM, Witherspoon RP, Scannon PJ, Friedmann N, Storb R: Evaluation of a CDS-specific immunotoxin for treatment of acute graft- versus-host disease after allogeneic marrow transplantation. Stood (1996) 88:824-30.
68. Van Oijen MG, Prefers FW: Rationale for the use of immunotoxins in the treatment of HIV-infected humans. JDrug Targeting (1998) 5:75-91.
69. Ramachandran RV, Katzenstein DA, Wood R, Batts DH, Merigan TC: Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-Infected persons. J Infect Dis (1994) 170:1009-13.
70. Pincus SH: Therapeutic potential of anti-HIV immunotoxins. Antiviral Res (1996) 33:1-9.
71. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG: Response of psoriasis to a lymphocyteselective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Wa/Med(1995) 1:442-7.
72. Christophers E: The immunopathology of psoriasis. Int Arch Allergy /mmuno/(1996) 110:199-206.
73. Wu M: Are immunoconjugates useful for therapy with autoimmune diseases? Int J Immunopharm (1997)19:83-93.
74. Uckun FM, Yanishevski Y, Turner N, Waurzyniak B, Messinger Y, Chelstrom LM, Usowski EA, Ek O, Zeren T, Wendorf H, Langue MC, Irvin JD, Myers DE, Fuller GB, Evans W, Günther R: Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19>pokeweed antiviral protein Immunotoxin In cynomolgus monkeys. Clin Cancer fies (1997) 3:325-37.
75. Puri RK, Hoon DS, Leland P, Snoy P, Rand RW, Pastan I, Kreitman RJ: Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res (1996) 56:5631-7.
76. Puri RK: Development of a recombinant lnterleukin-4-Pseuctomonas exotoxin for therapy of glioblastoma. Toxicol Pathol (1999) 27:53-7.
77. Weinberg AD: Antibodies to OX-40 (CD134) can Identify and eliminate autoreactive T cells: Implications for human autoimmune disease. MolMed Today (1998) 4:76-83. This article, along with reference 78, describes the profound beneficial effects of the depletion of pathogenic autoreactive T-cells with an immunotoxin prior to, and after, the onset of EAE in rats. Unfortunately, this reagent would not benefit MS patients as CD4+OX40+ T-cells do not increase in the clinically active disease (see reference 82). However, these observations support the hypothesis that depletion of pathogenic leukocytes with a selective targeting agent, is a viable therapeutic approach in diseases, such as MS.
78. Weinberg AD, Wegmann KW, Funatake C, Whitham RH: Blocking OX40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Imrnunol (\999) 162:1818-26. See reference 77.
79. Muraro PA, Martin R, Lassmann H, Gambi D: Plaques, T cells and beyond: report on an international meeting on the Immunological basis of multiple sclerosis held at the University of Chieti, Italy. J Weuro/mmuno/(1999) 96:251-4.
80. Schlier DJ, Schimmer RC, Flory CM, Tung DK, Ward PA: Role of chemokines and cytokines in a reactivation model of arthritis in rats induced by injection with streptococcal cell walls. J Leukocyte Biol (1998) 63:359-63.
81. Rodenburg RJ, van Den Hoogen FH, Barrera P, van Venrooij WJ, van De Putte LB: Superinduction of interleukin 8 mRNA in activated monocyte derived macrophages from rheumatoid arthritis patients. Ann Rheum Dis (1999) 58:648-52.
82. Hintzen RQ, Pot K, Paty D, Oger J: Analysis of effector CD4 (OX-40+) and CDS (CD45RA+CD27-) T lymphocytes in active multiple sclerosis. Acta NeurolScand(2000) 101:57-60. See reference 77.
83. Moreland LW, Sewell KL, Trentham DE, Bucy RP, Sullivan WF, Schrohénloher RE, Shmerling RH, Parker KG, Swartz WG, Woodworth TG et at. lnlerleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension. Arthritis Rheum (1995) 38:1177-86.
84. Schrohénloher RE, Koopman WJ, Woodworth TG, Moreland LW: Suppression of in vitro IgM rheumatoid factor production by diphtheria toxin interleukin 2 recombinant fusion protein (DAB 486IL-2) in patients with refractory rheumatoid arthritis. J fl/7eumato/(1996) 23:1845-8.
85. DiSepio D, Chandraratna RAS, Nagpal S: Novel approaches for the treatment of psoriasis. Drug Disc Today (1999) 4:222-31.
86. Konig A, Krenn V, Gillitzer R, Glockner J, Janssen E, Gohlke F, Eulert J, Muller-Hermelink HK: Inflammatory infiltrate and interleukin-8 expression In the synovium of psoriatic arthritis-an immunohistochemlcal and mRNA analysis. Rheumalol Int (1997) 17:159-68.
87. Terui T, Ozawa M, Tagami H: Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp Dermatol(2QOO) 9:1-10.
88. Siegall CB, Liggitt D, Chace D, Mixan B, Sugai J, Davidson T, Steinitz M: Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based Immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin Cancer Res (1997) 3:339-45.
89. Zlotnik A, Morales J, Hedrick JA: Recent advances in chemokines and chemokine receptors. Cri(flev/mmuno/(1999) 19:1-47.
90. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA: International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000) 52:145-76.
91. Downey GP, Granton JT: Mechanisms of acute lung injury. Curr Opin Pulm Med ( 1997) 3:234-41.
92. Strieter RM, Kunkel SL, Keane MP, Standiford TJ: Chemokines In lung injury: Thomas A. Neff Lecture. Chest (1999) 116:103S-110S.
93. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ: A new class of membrane-bound chemokine with a CX3C motif. Nature (1997) 385:640-4.
94. Nisniyori A, Minami M, Ohtani Y, Takarni S, Yamamoto J, Kawaguchi N, Kume T, Akaike A, Satoh M: Localization of fractalkine and CX3CR1 mRNAs In rat brain: does fractalkine play a role In signaling from neuron to microglia? FEES Lett (1998) 429:167-72.
95. Keane MP, Wfflke CA, Burdick MD, Morris SB, Glass MC, Strieter RM: CXC chemokines regulate angiogenic activity in acute lung injury. Chest (1999)116:93S-94S.
96. Keane MP, Strieter RM: The role of CXC chemokines in the regulation of angiogenesis. Chemlmmunol (1999) 72:86-101.
97. Driscoll KE: Macrophage inflammatory proteins: biology and role in pulmonary inflammation. Exp Lung Res (1994) 20:473-90.
98. Youn BS, Zhang SM, Lee EK, Park DH, Broxmeyer HE, Murphy PM, Local! M, Pease JE, Kim KK, Antol K, Kwon BS: Molecular cloning of leukotactin-1: a novel human beta-chemokine, a chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC chemokine receptors 1 and 3. J Immunol (1997) 159:5201-5.
99. Johnston B, Bums AR, Suematsu M, Issekutz TB, Woodman RC, Kubes P: Chronic inflammation upregulates chemokine receptors and induces neutrophil migration to monocyte chemoattractant protein-1. JClin /nvesf (1999) 103:1269-1276.
100. Ueda H, Siani MA, Gong W, Thompson DA, Brown GG, Wang JM: Chemically synthesized SDF-1a analogue, N33A, is a potent chemotactic agent for CXCR4/Fusin/LESTR-expressing human leukocytes. JB/o/Chem(1997) 272:24966-70.
101. Wells TN, Power CA, Proudfoot AE: Definition, function and pathophysiological significance of chemokine receptors. Trends Pharmacol Sei (1998) 19:376-80.
102. Mantovani A: The chemokine system: redundancy for robust outputs. Immunol Today (1999) 20:254-7.
103. Devalaraja MN, Richmond A: Multiple chemotactic factors: fine control or redundancy? Trends Pharmacol Sei (1999) 20:151-6.
104. Man KH, Tangirala RK, Green SR, Quehenberger O: Chemokine receptor CCR2 expression and monocyte chemoattractant protein1-mediated chemotaxis In human monocytes. A regulatory role for plasma LDL. Arterioscler Thromb Vase B/o/(1998) 18:1983-91.
105. Boddeke EW, Meigel I, Frentzel S, Gourmala NG, Harrison JK, Buttini M, Spleiss O, Gebicke-Harter P: Cultured rat microglia express functional beta-chemokine receptors. J Neuroimmunol (1999) 98:176-84. :
106. Zhang S, Youn BS, Gao JL, Murphy PM, Kwon BS: Differential effects of leukotactin-1 and macrophage inflammatory protein-1 alpha on neutrophils mediated by CCR1. J/mmuno/(1999) 162:4938-42.
107. Murphy PM: Neutrophil receptors for interIeukin-8 and related CXC chemokines. Semin Hemaîo/(1997) 34:311-8.
108. Gerber BO, Zanni MP, Uguccioni M, Loetscher M, Mackay CR, Pichler WJ, Yawalkar N, Baggiolini M, Moser B: Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils. Curr B/o/ (1997) 7:836-43.
109. Sallusto F, Mackay CR, Lanzavecchia A: Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science (1997) 277:2005-7.
110. 110/ Annunziato F, Cosmi L, Galli G, Beltrame C, Romagnani P, Manetti R, Romagnani S, Maggi E: Assessment of chemokine receptor expression by human Th1 and Th2 cells In vitro and in vivo. J Leukocyte B/o/(1999) 65:691-9.
111. Rabin RL, Park MK, Liao F, Swofford R, Stephany D, Farber JM: Chemokine receptor responses on T Cells are achieved through regulation of both receptor expression and signaling. J Immunol (1999)162:3840-3850.
112. Vaddi K, Newton RC: Comparison of biological responses of human monocytes and THP-1 cells to chemokines of the intercrine-beta family. J Leukocyte Biol (1994) 55:756-62.
113. Valkovic T, Lucin K, Krstulja M, Dobi-Babio R, Jonjic N: Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. PatholRes Pract (1998) 194:335-40.
114. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Strom SR, Burdick MO, lannettoni MD, Strieter RM: Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother (2000) 49:63-70.
115. Negus RP, Stamp GW, Hadley J, Balkwill FR: Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol (1997)150:1723-34.
116. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ: Human endothelial cells express CCR2 and respond to' MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood (2000) 96:34-40. This is the first report that describes a direct role of a CC chemoldne (MCP-1) and its cognate receptor (CCR2) in angiogenesis and human tumor progression.
117. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR: The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. P roc Natl Acad Sei USA (1997) 94:1925-30.
118. Bleul CC, Schultze JL, Springer TA: B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement. J Exp Med (1998) 187:753-62.
119. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM: Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and Its transcriptional regulation by inflammatory cytokines. J/o/Cnem (1998) 273:4282-7.
120. Sehgal A, Keener C, Boynton AL, Warrick J, Murphy GP: CXCR-4, a Chemokine receptor, is overexpressed in and required for proliferation of gliobtastoma tumor cells. J Surg Onco/(1998) 69:99104.
121. Zaitseva MB, Lee S, Rabin RL, Tiffany HL, Farber JM, Peden KW, Murphy PM, Golding H: CXCR4 and CCRS on human thymocytes: biological function and role in HIV- 1 infection. J Immunol (1998) 161:3103-13.
122. Gupta SK, Pillarisetti K, Lysko PG: Modulation of CXCR4 expression and SDF-1a functional activity during differentiation of human monocytes and macrophages. J Leukocyte /o/(1999) 66:135-43.
123. Jordan NJ, Kolios G, Abbot SE, Sinai MA, Thompson DA, Petraki K, Westwick J: Expression of functional CXCR4 Chemokine receptors on human colonie epithelial cells. JClin Invest (1999) 104:1061-9.
124. Molino M, Woolkalis MJ, Prévost N, Pratico D, Bamathan ES, Taraboletti G, Haggarty BS, Hesselgesser J, Horuk R, Hoxie JA, Brass LF: CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2. Biochim BiophysActa (2000) 1500:227-240.
125. Nagase H, Miyamasu M, Yamaguchi M, Fujisawa T, Ohta K, Yamamoto K, Monta Y, Hirai K: Expression of CXCR4 in eosinophils: functional analyses and cytokine- mediated regulation. J Immunol (2000) 164:5935-43.
126. Rempel SA, Dudas S, Ge S, Gutierrez JA: Identification and localization of the cytokine SDF1 and its receptor, CXC Chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res (2000) 6:102-11. TTie SDF-1 receptor CXCR4, is expressed in tumor, phagocytic and neovessel endothelial cells in human glioblastoma. This suggests that the chemokine-toxin OPL-9B111, described in this paper, would be a powerful agent in the treatment of certain human brain tumors.
127. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM: Inhibition of interleukin-8 reduces tumorigenesis of human non-small ceil lung cancer In SCID mice. J Clin Invest (1996) 97:2792-802.
128. Desbaillets I, Diserens AC, de Tribolet N, Hamou MF, Van Meir EG: Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogens (1999) 18:1447-56.
129. Strieter RM, Polverini PJ, Arenberg DA, Walz A, Opdenakker G, Van Damme J, Kunkel SL: Role of C-X-C chemoklnes as regulators of angiogenesis in lung cancer. J Leukocyte Biol (1995) 57:752-62.
130. Blair WS, Un PF, Meanwell NA, Wallace OB: HIV-1 entry - an expanding portal for drug discovery. Drug Disc Today (2000) 5:183-194.
131. Menzies-Gow A, Robinson DS: Eosinophil chemoklnes and their receptors: an attractive target in asthma? Lancet (2000) 355:1741-3.
132. Rankin SM, Conroy DM, Williams TJ: Eotaxin and eosinophil recruitment: implications for human disease. Mol Med Today (2000) 6:20-7.
133. Sampson AP: The role of eosinophils and neutrophils in inflammation. Clin Exp Allergy (2000) 30(Suppl 1):22-7.
134. Balashov KE, Rottman JB, Weiner HL, Hancock WW: CCR5(+) and CXCR3(+) T cells are increased In multiple sclerosis and their ligands MIP-1a and IP-10 are expressed In demyelinating brain lesions. Proc Natl Acad Sei USA (1999) 96:6873-8.
135. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM: Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest (1999)103:807-15.
136. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN: Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol (2000) 26:133-42.
137. Takahashi Y, Kasahara T, Sawai T, Rikimaru A, Mukaida N, Matsushima K, Sasaki T: The participation of IL-8 in the synovial lesions at an early stage of rheumatoid arthritis. Tohoku J Exp Med (1999)188:75-87.
138. Wedderbum LR, Robinson N, Patel A, Varsani H, Woo P: Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum (2000) 43:765-74.
139. Jarvis B, Markham A: Montelukast: a review of its therapeutic potential In persistent asthma. Drugs (2000) 59:891-928.
140. Martinet Y, Menard O, Vaillant P, Vignaud JM, Martinet N: Cytokines In human lung fibrosis. Arch Toxicol Suppl (1996) 18:127-39.
141. Agostini C, Siviero M, Semenzato G: Immune effector cells in idiopathic pulmonary fibrosis. CurrOpin Pulm Mee/(1997) 3:348-55.
142. Gipson TS, Bless NM, Shanley TP, Crouch LD, Bleavins MR, Younkin EM, Sarma V, Gibbs DF, Tefera W, McConnell PC, Mueller WT, Johnson KJ, Ward PA: Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. J Immunol (1999)162:3653-62.
143. Kunkel SL, Lukacs NW, Strieter RM, Chensue SW: The role of chemokines in the immunopathology of pulmonary disease. Forum (Geneva) (1999) 9:339-55.
144. Bellanti JA: Cytokines and allergic diseases: clinical aspects. Allergy Asthma Proc (1998) 19:337-41.
145. Teran LM: CCL chemokines and asthma. Immunol Today (2000) 21:235-42.
146. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD: Scavenger receptor-mediated adhesion of microglia to betaamyloid fibrils. Nature (1996) 382:716-9.
147. Meda L, Bemasconi S, Bonaiuto C, Sozzani S, Zhou D, Otvos L, Jr, Mantovani A, Rossi F, Cassatella MA: Beta-amyloid (25-35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes and microglial cells. J Immunol(I996) 157:1213-8.
148. El Khoury J, Hickman SE, Thomas CA, Loike JD, Silverstein SC: Microglia, scavenger receptors, and the pathogenesis of Alzheimer's disease. Neurobiol Aging (1998) 19:381-4.
149. Xia MO, Qin SX, Wu U, Mackay CR, Hyman BT: Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. AmJPathol(1998) 153:31-7.
150. McGeer EG, McGeer PL: The importance of inflammatory mechanisms in Alzheimer disease. Exp Geronto/(1998) 33:371-8.
151. Weidemann A, Paliga K, Dürrwang U, Reinhard FB, Schuckert O, Evin G, Masters CL: Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases. JB/o/Criem(1999) 274:5823-9.
152. Xia MQ, Hyman BT: Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neuroviml (1999) 5:3241.
153. Camp BJ, Dyhrman ST, Memoli VA, Mort LA, Barth Jr RJ: In situ cytokine ' production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Onco/(1996) 3:176-84.
154. Inoue K, Siaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP: Interleukin 8 expression regulates tumorigenicity and métastases in androgenindependent prostate cancer. Clin CancerRes (2000) 6:2104-19.
155. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Stricter RM. CXC chemokines in angiogenesis. J Leukocyte Biol (2000)68:1-8.
156. Watanabe T, Fan J: Atherosclerosis and inflammation mononuclear cell recruitment and adhesion molecules with reference to the implication of ICAM-1/LFA-1 pathway in atherogenesis. Int J Cardiol (1993) 66(Suppl 1):S45-53.
157. Gerszten RE, Mach F, Sauty A, Rosenzweig A, Luster AD. Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med (2000)136:87-92.
158. Hong BK, Kwon HM, Lee BK, Kirn D, Kim IJ, Kang SM, Jang Y, Cho SH, Kim HK, Jang BC, Cho SY, Kim HS, Kim MS, Kwon HC, Lee N: Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J (2000) 41:828.
159. Kelley JL, Chi DS, Abou-Auda W, Smith JK, Krishnaswamy G: The molecular role of mast cells in atherosclerotic cardiovascular disease. Mol Med Today (2000) 6:304-308.
160. Sullivan GW, Sarembock IJ, Linden J: The role of inflammation in vascular diseases. J Leukocyte Blot (2000) 67:591 -602.
161. Bames PJ: Chronic obstructive pulmonary disease: new opportunities for drug development. Trends Pharmacol Sei (1998) 19:415-23.
162. Anderson GP, Shinagawa K: Neutrophil elastase inhibitors as treatments of emphysema and chronic bronchitis. Curr Opin Antiinflamm Immunomod Invest Drugs (1999) 1:29-38.
163. Mohammed S, Young A: Clinical aspects and treatment of chronic obstructive pulmonary disease. Curr Opin Antiinflamm Immunomod Invest Drugs (1999) 1:21-8.
164. Shapiro SD: The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1999) 160:329-32.
165. Hill GR, Krenger W, Ferrara JL: The role of cytokines in acute graftversus-host disease. Cytokines Cell Mol 7/ier(1997) 3:257-66.
166. Ferrara JL, Levy R, Chao NJ: Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant (1999) 5:347-56.
167. Murphy WJ, Blazar BR: New strategies for preventing graft-versushost disease. Curr Opin Immunol (1999) 11:509-15.
168. Fox A, Ham'son LC: Innate immunity and graft rejection. Immunol Rev (2000) 173:141-7.
169. Emilie D, Galanaud P: Cytokines and chemokines in HIV infection: implications for therapy. Int Rev Immunol (1998)16:705-26.
170. Zrieng J, Thylin MR, Ghorpade A, Xiong H, Persidsky Y, Cotter R, Niemann D, Che M, Zeng YC, Gelbard HA, Shepard RB, Swartz JM, Gendelman HE: Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1-associated dementia. J Neuro/mmuno/(1999) 98:185-200.
171. Wu DT, Woodman SE, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser J, Major EO, Nath A, Berman JW: Mechanisms of leukocyte trafficking into the CNS. J Neurovirol (2000) 6(Suppl 1):S82-5.
172. Kolios G, Petoumenos C, Nakos A: Mediators of inflammation: production and implication in inflammatory bowel disease. HepatoGastro (1998) 45:1601-9.
173. MacDermott RP, Sanderson IR, Reinecker HG: The central role of chemokines (chemotactic cytokines) In the immunopathogenesis of ulcerative colitis and Crohn's disease. Inflamm Bowel Dis (1998) 4:54-67.
174. Boismenu R, Chen Y: Insights from mouse models of colitis. J Leukocyte Biol (2000) 67:267-78.
175. Sheridan RL, Ryan CM, Yin LM, Hurley J, Tompkins RG: Death in the burn unit: sterile multiple organ failure. Bums (1998) 24:307-11.
176. Faunce DE, Uanas JN, Patel PJ, Gregory MS, Duffner LA, Kovacs EJ: Neutrophil chemokine production in the skin following scald injury. Bums (1999) 25:403-10.
177. Muruve DA, Bames MJ, Stillman IE, Libermann TA: Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Trier (1999) 10:965-76.
178. Williams MA, Cave CM, Quaid G, Solomkin JS: Chemokine regulation of neutrophil function In surgical inflammation. Arch Surg (1999) 134:1360-6.
179. Lin E, Galvano SE, Lowry SF: Inflammatory cytokines and cell response in surgery. Surgery (2000) 127:117-26.
180. Benveniste EN: Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med (1997) 75:165-73.
181. Yong VW, Chabot S, Stuve O, Williams G: Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology (1998) 51:682-9.
182. Esser P, Heimann K, Wiedemann P: Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. BrJOphthalmol (1993) 77:731-3.
183. Esser P, Bresgen M, Fischbach R, Heimann K, Wiedemann P: Intercellular adhesion moleeule-1 levels in plasma and vitreous from patients with vitreoretinal disorders. G er J Ophthalmol (1995) 4:269-74.
184. Capeans C, De Rojas MV, Lojo S, Salorio MS: C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina (1998) 18:546-50.
185. Bonifati C, Ameglio F: Cytokines in psoriasis. Int J Dermatol (1999) 38:241-51.
186. Karasek MA: Progress in our understanding of the biology of psoriasis. Cutis (1999) 64:319-22.
187. Szekanecz 2, Szegedi G, Koch AE: Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Invest Med (1998) 46:27-41.
188. Gerti R, Pitzalis C, Bistoni O, Falini B, Costantini V, Russano A, Lunardi C: CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. Jlmmunol (2000) 164:4399-407.
189. Konig A, Krenn V, Toksoy A, Gerhard N, Gillitzer R: Mig, GRO alpha and RANTES messenger RNA expression in lining layer, infiltrates and different leukocyte populations of synovial tissue from patients with rheumatoid arthritis, psoriatic arthritis and osleoarthritis. Virchows Arch'(2000) 436:449-58.
190. Szekànecz Z, Halloran MM, Volin MV, Woods JM, Strieter RM, Kenneth Haines G 3rd, Kunkel SL, Burdick MD, Koch AE: Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis flheum (2000) 43:1266-77.
191. Taoka Y, Okajima K, Uchiba M, Murakami K, Kushimoto S, Johno M, Naruo M, Okabe H, Takatsuki K: Role of neutrophils in spinal cord injury in the rat. Neuroscience (1997) 79:1177-82. See reference 191.
192. Carlson SL, Parrish ME, Springer JE, Doty K, Dossett L Acute inflammatory response In spinal cord following impact Injury. Exp Weuro/(1998) 151:77-88. This article and reference 190 describes the temporal nature of the pathological roles of different leukocyte populations in SCI. Leukocyte depletion in a. rat spinal cord contusion model markedly attenuated intramedullary hemorrhages' and motor disturbances. Selective macrophage depletion using the same animal model is also beneficial by promoting partial hindümb recovery and neuroanatomical repair (Popovlch et al: Exp Neurol (1999) 158:351-65).
193. Isaksson J, Farooque M, Holtz A, Hillered L, Olsson Y: Expression of ICAM-1 and CD11b after experimental spinal cord injury in rats. J Neumtrauma (1999) 16:165-73.
194. Beliingan G: Inflammatory cell activation in sepsis. Br Med Bull (1999)55:12-29.
195. Karima R, Matsumoto S, Higashi H, Matsushima K: The molecular pathogenesis of endotoxic shock and organ failure. Mol Med Today (1999) 5:123-32.
196. Fry DE: Sepsis syndrome. Am Surg (2000) 66:126-32.
197. DeGraba TJ: The role of inflammation after acute stroke: utility of pursuing anti- adhesion molecule therapy. Neurology (1998) 51:562-8.
198. Barone FC, Feuerstein GZ: Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab (1999)19:819-34.
199. Pantoni L, Sard C, Inzitari D: Cytokines and cell adhesion molecules In cerebral ischemia: experimental bases and therapeutic perspectives. Arterioscler Thromb l/asc/b/(1998) 18:503-13.
200. Wang X, ü" X, Schmidt DB, Foley JJ, Barone FC, Ames RS, Sarau HM: Identification and molecular characterization of rat CXCR3: receptor expression and interferon-inducible protein-10 binding are increased in focal stroke. Mol Pharmacol (2000) 57:1190-8.
201. Sedlacek R, Mauch S, Kolb B, Schatzlein C, Eibel H, Peter HH, Schmitt J, Krawinkel U: Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. /mmunob/o/ogy(1998) 198:408-23.
202. Tesar V, Masek 7., Rychlik I, Merta M, Bartunkova J, Stejskalova A, Zabka J, Janatkova I, Fucikova T, Dostal C, Becvar R: Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant (1998) 13:1662-7.
203. Kaneko H, Ogasawara H, Naito T, Akimoto H, Lee S, Hishikawa T, Sekigawa I, Tokano Y, Takasaki Y, Hirose SI, Hashimoto H: Circulating levels of beta-chemokines in systemic lupus erythematosus. J fl/ieumato/(1999) 26:568-73.
204. Kelley VR, Wuthrich RP: Cytokines in the pathogenesis of systemic lupus erythematosus. Semin Nephrol (1999) 19:57-66.
205. Ghimikar RS, Lee YL, He TR, Eng LF: Chemokine expression In rat stab wound brain injury. J Neumsci Res (1996) 46:727-33.
206. Glabinski AR, Balasingam V, Tani M, Kunkel SL, Strieter RM, Yong VW, Ransohoff RM: Chemokine monocyte chemoattractant protein-1 Is expressed by astrocytes after mechanical injury to the brain. J /mmuno/(1996) 156:4363-8.
207. Feuerstein GZ, Wang X, Barone FC: The role of cytokines in the neuropathology of stroke and neurotrauma. Neuroimmunomodulation (1998)5:143-59.
208. Ghimikar RS, Lee YL, Eng LF: Inflammation in traumatic brain injury: role of cytokines and chemokines. Neurochem Res (1998) 23:329-40.
209. Whalen MJ, Cartos TM, Dixon CE, Robichaud P, Clark RS, Marion DW, Kochanek PM: Reduced brain edema after traumatic brain injury in mice deficient in P-selectin and Intercellular adhesion molecule-1. J Leukocyte (2000) 67:160-8.
210. Verma MJ, Uoyd A, Rager H, Strieter R, Kunkel S, Taub D, Wakefield D: Chemokines in acute anterior uveltis. CUIT Eye Res (1997) 16:1202-8.
211. Yang P, de Vos AF, Kijlstra A: Macrophages and MHC class II positive cells in the choroid during endotoxin induced uveitis. BrJ Op/7tfra/mo/(1997) 81:396-401.
212. Sakaguchi M, Sugita S, Sagawa K, Itoh K, Mochizuki M: Cytokine production by T cells Infiltrating in the eye of uveitis patients. Jpn J Ophthalmol(W38) 42:262-8.
213. Pouvreau l, Zech JC, Thillaye-Goldenberg B, Naud MC, Van Rooijen N, de Kozak Y: Effect of macrophage depletion by liposomes containing dichloromethylene-diphosphonate on endotoxinInduced uveitis. JNeuroimmunol(\9SQ) 86:171-81.
214. Kamali F: Rofecoxib. Curr Opin Cent Peripheral Nerv Syst Invest Drugs (1999)1:126-31.
215. Clemett D, Goa KL: Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs (2000) 59:957-80.
216. Jackson LM, Hawkey CJ: COX-2 selective nonsteroidal antiinflammatory drugs: do they really offer any advantages? Drugs (2000)59:1207-16.
217. Helms PJ: Corticosteroid-sparing options in the treatment of childhood asthma. Doigs(2000) 59:15-22.
218. Lebwohl M: Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol (2000) 43:843-6.
219. Pointillart V, Petitjean ME, Wiart L, Vital JM, Lassie P, Thicoipe M, Dabadie P: Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord (2000) 38:71-6.
220. Short DJ, El Masry WS, Jones PW: High dose methylprednisolone in the management of acute spinal cord injury - a systematic review from a clinical perspective. Spinal Cord (2000) 38:273-86.
221. Michaelides MR, Curtin ML: Recent advances in matrix metalloproteinase inhibitors research. Curr Pharm Design (1999) 5:787-819.
222. Yong VW: The potential use of MMP inhibitors to treat CNS diseases. Exp Opin Invest Drugs (1999) 8:255-68.
223. Price A, Shi Q, Morris D, Wilcox ME, Brasher PM, Rewcastle NB, Shalinsky D, Zou H, Appell K, Johnston RN, Yong VW, Edwards D, Forsyth P: Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase Inhibitor AG3340. Clin Cancer Res (1999) 5:845-54.
224. Horuk R, Ng HP: Chemokine receptor antagonists. Med Res Rev (2000)20:155-68.
225. Schwarz MX, Wells TN: Interfering with Chemokine networks-the hope for new therapeutics. CurrOpin Chem Biol (1999) 3:407-17.
226. Lange R: Interleukin 4 receptor. Curr Opin Antiinflamm Immunomod Invest Drugs ( 1999) 1:73-8.
227. Dent G: Sch-55700. Curr. Opin Antiinflamm Immunomod Invest Drugs (1999) 1:51-5.
228. Brown E:'Neutrophil adhesion and the therapy of inflammation. Semin Hemato/(1997) 34:319-26.
229. Un KG, Castro AC: Very late antigen 4 (VLA4) antagonists as antiinflammatory agents. Curr Opin Chem Biol (1998) 2:453-7.
230. Elices MJ: Blockade of the VLA-4 integrin as a therapy for airway inflammation in respiratory disease. Curr Opin Antiinflamm Immunomod Invest Drugs (1999) 1:14-20.
231. Pradella L: TBC-1269. Curr Opin Antiinflamm Immunomod Invest Drugs (1999) 1:56-60.
232. Cherrington JM, Strawn LM, Shawver LK: New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res (2000) 79:1-38.
233. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA: Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin avb3. Clin Cancer Res (2000) 6:3056-61.
234. Yong VW, Antel JP: Culture of glial cells from human brain biopsies. In: Protocols for Neural cell Culture. Richardson A, Fedoroff S (Eds), Humana Press, St Louis, (1997):157-172.
235. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 65:55-63.
236. Gieni RS, Li Y, HayGlass KT: Comparison of ['H]thymidine incorporation with MTT- and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. J Immunol Methods (1995) 187:85-93.